This white paper from Abbott examines a cross-section of the global healthcare system leveraging primary research with 1,400+ respondents including patients, physicians, and administrators.

AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.

RA Capital Management closed the venture capital firm’s second venture fund at $461 million, aimed at a continued investment strategy into privately held life sciences companies.

Fernando Fernandez, Managing Director of FCB Health Network’s BX – Brand Experience Design Group, talked to Med Ad News about how COVID-19 has changed the way people interact with brands, how branding innovations such as audio and motion identities are making their way to pharma, and other topics.

EVERSANA launched ACTICS by EVERSANA, a technology-enabled solution to optimize end-to-end commercial success for life science companies.

Fingerpaint, a full-service health and wellness agency with five offices across the United States and nearly $80 million in revenue, announced that Nick Bartolomeo and Bryan O’Malley have been promoted to head of media and performance marketing and head of technology and performance innovation, respectively.

Blue Knight, a program created in partnership with Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA), chose seven startups from J&J’s global JLABS incubator network to participate in the fight against the world’s current Covid-19 pandemic and future ones.

In this webinar, learn how diverse drug development companies with unique models of discovery, innovative drug modalities and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds’ disease impact.

Everyone knows the terms “machine learning” and “artificial intelligence.” Few can define them, much less explain their inestimable value to clinical trials. So, it’s not surprising that, despite their ability to minimize risk, improve safety, condense timelines, and save costs, these technology tools are not widely used by the clinical trial industry. 

Longwood Fund closed the early-stage investment group’s fifth fund, which will be used to support the launch of new companies as well as the growth of startups in the life sciences space.